GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spark Therapeutics Inc (NAS:ONCE) » Definitions » Equity-to-Asset

Spark Therapeutics (Spark Therapeutics) Equity-to-Asset : 0.49 (As of Sep. 2019)


View and export this data going back to 2015. Start your Free Trial

What is Spark Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Spark Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2019 was $346.01 Mil. Spark Therapeutics's Total Assets for the quarter that ended in Sep. 2019 was $703.50 Mil. Therefore, Spark Therapeutics's Equity to Asset Ratio for the quarter that ended in Sep. 2019 was 0.49.

The historical rank and industry rank for Spark Therapeutics's Equity-to-Asset or its related term are showing as below:

ONCE's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

Spark Therapeutics Equity-to-Asset Historical Data

The historical data trend for Spark Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spark Therapeutics Equity-to-Asset Chart

Spark Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Equity-to-Asset
Get a 7-Day Free Trial 0.61 0.88 0.88 0.83 0.61

Spark Therapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 0.61 0.60 0.54 0.49

Competitive Comparison of Spark Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Spark Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spark Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spark Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Spark Therapeutics's Equity-to-Asset falls into.



Spark Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Spark Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Equity to Asset (A: Dec. 2018 )=Total Stockholders Equity/Total Assets
=496.513/814.352
=0.61

Spark Therapeutics's Equity to Asset Ratio for the quarter that ended in Sep. 2019 is calculated as

Equity to Asset (Q: Sep. 2019 )=Total Stockholders Equity/Total Assets
=346.009/703.5
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spark Therapeutics  (NAS:ONCE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Spark Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Spark Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Spark Therapeutics (Spark Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3737 Market Street, Suite 1300, Philadelphia, PA, USA, 19104
Spark Therapeutics Inc is a biotechnology company with a focus on gene therapy and orphan disease treatment. The company has one business segment, Pharmaceuticals, which is principally engaged in utilizing gene therapy to develop products to aid patients suffering from debilitating diseases. Spark has a pipeline with products that target choroideremia, genetic blinding conditions or inherited retinal disease, and a product targeting hematologic disorders. The company earns the vast majority of its revenue in the United States.
Executives
Elliot Sigal director
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Stephen W Webster officer: CHIEF FINANCIAL OFFICER C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel Faga officer: Chief Business Officer 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Lota S. Zoth director, officer: CHIEF SCIENTIFIC OFFICER 334 CR 692, BUFFALO GAP TX 79508
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Robert J Perez director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER ST., WALTHAM MA 02451
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Roche Holding Ltd 10 percent owner ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Katherine A High director, officer: See Remarks 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John Furey officer: Chief Operating Officer 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Vivaldi Coelho Rogerio officer: Chief Commercial Officer 225 SECOND AVENUE, WALTHAM MA 02451
Srinivas Akkaraju 10 percent owner 565 EVERETT AVENUE, PALO ALTO CA 94301
Sofinnova Venture Partners Viii, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025

Spark Therapeutics (Spark Therapeutics) Headlines

From GuruFocus